Millennium: The Takeda Oncology Company and its Japanese parent company said Wednesday that European regulators have granted conditional marketing authorization for ADCETRIS, a drug for some forms of lymphoma, a general term for a group of cancers that originate in the lymphatic system. Takeda Pharmaceutical Co. Ltd. said it intends to launch ADCETRIS across Europe in the coming weeks. (Takeda Pharmaceutical bought Cambridge-based Millennium in 2008 for $8.8 billion.)
Unlimited access to BostonGlobe.com for only 99 cents for the first 4 weeks.Sign up
Are you a home delivery subscriber?
Get FREE access as part of your print subscriptionStart Here
Contact us for help